We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+9.76%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$210M
AUM Growth
-$50M
Cap. Flow
-$601K
Cap. Flow %
-0.29%
Top 10 Hldgs %
49.98%
Holding
57
New
3
Increased
11
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$7.1M
2
CELG
Celgene Corp
CELG
+$5.66M
3
ZGNX
Zogenix, Inc.
ZGNX
+$5.6M
4
INCY icon
Incyte
INCY
+$5.08M
5
EXEL icon
Exelixis
EXEL
+$5.07M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$14.5M
2
BIIB icon
Biogen
BIIB
+$10.5M
3
SAGE
Sage Therapeutics
SAGE
+$4.17M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.82M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
26
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.79M 1.32%
21,600
+5,400
+33% +$929K
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
$2.51M 1.19%
42,500
– –
XENT
28
DELISTED
Intersect ENT, Inc
XENT
$2.47M 1.17%
112,000
– –
DCPH
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.29M 1.09%
77,000
– –
AGIO icon
30
Agios Pharmaceuticals
AGIO
$2.05B
$2.16M 1.03%
36,500
– –
IONS icon
31
Ionis Pharmaceuticals
IONS
$10.4B
$2.04M 0.97%
51,500
-75,000
-59% -$3.52M
BLUE
32
DELISTED
bluebird bio
BLUE
$1.9M 0.9%
1,312
-232
-15% -$479K
SAGE
33
DELISTED
Sage Therapeutics
SAGE
$1.73M 0.82%
15,996
-27,000
-63% -$4.17M
STRO icon
34
Sutro Biopharma
STRO
$353M
$1.69M 0.8%
+14,665
New +$2.21M
MDGL icon
35
Madrigal Pharmaceuticals
MDGL
$12.6B
$1.64M 0.78%
10,000
– –
KYNB
36
Kyntra Bio
KYNB
$32.4M
$1.46M 0.7%
1,256
– –
SGMO
37
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.46M 0.7%
113,000
– –
GWPH
38
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.27M 0.6%
9,600
– –
GMED icon
39
Globus Medical
GMED
$11.1B
$1.26M 0.6%
29,000
– –
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
$1.23M 0.59%
145,000
– –
MRUS
41
DELISTED
Merus
MRUS
$1.14M 0.54%
75,060
– –
HZNP
42
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.04M 0.49%
69,000
– –
ACAD icon
43
Acadia Pharmaceuticals
ACAD
$5.12B
$1.03M 0.49%
+65,000
New +$1.02M
SUPN icon
44
Supernus Pharmaceuticals
SUPN
$2.57B
$809K 0.38%
20,953
– –
PRTK
45
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$766K 0.36%
103,500
– –
CRVS icon
46
Corvus Pharmaceuticals
CRVS
$1.24B
$710K 0.34%
108,000
+26,659
+33% +$267K
FSTX
47
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$673K 0.32%
18,250
– –
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$543K 0.26%
58,600
– –
ONCE
49
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$502K 0.24%
12,000
– –
RDUS
50
DELISTED
Radius Health, Inc.
RDUS
$257K 0.12%
18,799
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2018 Portfolio in Review

As of Q3 2018, International Biotechnology Trust held 57 positions worth $210M, down 19% from $260M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

International Biotechnology Trust's Q3 2018 filing shows 3 new, 11 increased, 5 reduced and 6 closed positions. Its largest new stake was Zogenix, Inc.: 110,000 shares worth $4.18M. The largest sale was Neurocrine Biosciences, an estimated $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2018 buy was Zogenix, Inc.: 110,000 shares worth $4.18M.
  • International Biotechnology Trust added most to Aerie Pharmaceuticals in Q3 2018, an estimated $7.1M increase.
  • International Biotechnology Trust's biggest Q3 2018 reduction was Neurocrine Biosciences, cutting an estimated $14.5M.
  • International Biotechnology Trust fully exited Biogen in Q3 2018, selling an estimated $10.5M.
  • International Biotechnology Trust's ten largest holdings make up 50% of its $210M portfolio in Q3 2018.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q3 2018.
  • International Biotechnology Trust's portfolio value fell 19% quarter-over-quarter to $210M.

Based on International Biotechnology Trust's 13F filing for Q3 2018, filed 13 Nov 2018.